Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of zanubrutinib with the R-CHOP regimen in newly diagnosed non-GCB Diffuse Large B-Cell Lymphoma with double…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: Fudan University | Conditions: Diffuse Large B-cell Lymphoma(DLBCL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING